Abstract:Background and PurposeMetformin, a small molecule, antihyperglycaemic agent, is a well-known activator of AMP-activated protein kinase (AMPK) and protects against cardiac fibrosis. However, the underlying mechanisms remain elusive. TGF1 is a key cytokine mediating cardiac fibrosis. Here, we investigated the effects of metformin on TGF1 production induced by angiotensin II (AngII) and the underlying mechanisms. Experimental ApproachWild-type and AMPK2(-/-) C57BL/6 mice were injected s.c. with metformin or saline and infused with AngII (3mgkg(-1)day(-1)) for 7days. Adult mouse cardiac fibroblasts (CFs) were isolated for in vitro experiments. Key ResultsIn CFs, metformin inhibited AngII-induced TGF1 expression via AMPK activation. Analysis using bioinformatics predicted a potential hepatocyte nuclear factor 4 (HNF4)-binding site in the promoter region of the Tgfb1 gene. Overexpressing HNF4 increased TGF1 expression in CFs. HNF4 siRNA attenuated AngII-induced TGF1 production and cardiac fibrosis in vitro and in vivo. Metformin inhibited the AngII-induced increases in HNF4 protein expression and binding to the Tgfb1 promoter in CFs. In vivo, metformin blocked the AngII-induced increase in cardiac HNF4 protein levels in wild-type mice but not in AMPK2(-/-) mice. Consequently, metformin inhibited AngII-induced TGF1 production and cardiac fibrosis in wild-type mice but not in AMPK2(-/-) mice. Conclusions and ImplicationsHNF4 mediates AngII-induced TGF1 transcription and cardiac fibrosis. Metformin inhibits AngII-induced HNF4 expression via AMPK activation, thus decreasing TGF1 transcription and cardiac fibrosis. These findings reveal a novel antifibrotic mechanism of action of metformin and identify HNF4 as a new potential therapeutic target for cardiac fibrosis. Linked ArticlesThis article is part of a themed section on Spotlight on Small Molecules in Cardiovascular Diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.8/issuetoc

Metformin attenuates angiotensin II-induced TGFβ1 expression by targeting hepatocyte nuclear factor-4-α.